How the Eczema Guidelines Rank Biologics and JAK Inhibitors

The 2024 American Academy of Dermatology (AAD) guideline on systemic treatment of atopic dermatitis gives its strongest endorsement, a "strong recommendation," to five agents at once: the biologics dupilumab and tralokinumab and the oral Janus kinase (JAK) inhibitors abrocitinib, baricitinib, and upadacitinib. That shared top grade is the part readers most often misread. A strong recommendation reflects the workgroup's confidence that benefits outweigh harms for most eligible adults; it is not a safety score, and it does not absorb the class boxed warning that the U.S. Food and Drug Administration requires for the JAK inhibitors and not for the two antibodies.

What a recommendation grade actually measures

The guideline, published by Davis and colleagues in the Journal of the American Academy of Dermatology (online November 2023, in print February 2024), updates the 2014 guidance and issues eleven recommendations built on the GRADE method. GRADE separates two questions that casual readers tend to merge. The first is the strength of a recommendation: "strong" means the panel is confident the desirable effects clearly outweigh the undesirable ones for almost everyone who qualifies, while "conditional" signals a closer call that depends more heavily on an individual's circumstances and preferences. The second is the certainty of the underlying evidence, rated high, moderate, or low, which describes how much the estimated effect might change as more data arrive. A drug can earn a strong recommendation and still carry meaningful risks; the grade summarizes the balance of benefit and harm, not the absence of harm.

Where the biologics and JAK inhibitors landed

Under that framework, dupilumab, tralokinumab, abrocitinib, baricitinib, and upadacitinib all received strong recommendations for adults with moderate-to-severe disease. Older systemic options fared differently: the guideline gives conditional recommendations in favor of phototherapy, azathioprine, cyclosporine, methotrexate, and mycophenolate, and it recommends against routine use of systemic corticosteroids. Two features of this structure are easy to miss. The guideline grades each therapy against its own evidence rather than publishing a single ranked ladder from best to worst, so a shared "strong" label does not mean the five agents are interchangeable. And the recommendation tracks evidence, not only regulatory status: baricitinib earned a strong recommendation for atopic dermatitis even though its U.S. approvals lie in other conditions, a reminder that a specialty-society recommendation and an FDA label are separate instruments.

Why "strong" and "boxed warning" can describe the same drug

The safety signal that dominates public conversation about JAK inhibitors sits on a different axis entirely. On September 1, 2021, the FDA completed its review of ORAL Surveillance, a large randomized trial of the JAK inhibitor tofacitinib against tumor necrosis factor (TNF) inhibitors in rheumatoid arthritis patients aged fifty and older with at least one cardiovascular risk factor. The trial did not show that tofacitinib was non-inferior for major adverse cardiovascular events or malignancy, and it flagged increased blood clots and death. The agency then required a class boxed warning across the oral JAK inhibitors covering serious infections, mortality, major adverse cardiovascular events, malignancy, and thrombosis, and it narrowed the affected labels to reserve those drugs for patients who had not responded to or could not tolerate TNF blockers.

The atopic dermatitis JAK inhibitors carry that same class warning. Abrocitinib and upadacitinib were not tested in ORAL Surveillance, but they share the mechanism and the label language; their approvals likewise reserve them for disease not adequately controlled by other systemic drugs, including biologics, or when those are not advisable. Dupilumab and tralokinumab, which block interleukin signaling rather than JAK pathways, carry no such boxed warning. So the identical "strong recommendation" that the AAD applies to a JAK inhibitor and to a biologic rests on very different harm profiles. The grade answers a population-level question about average benefit versus harm; the boxed warning answers a regulatory question about serious, if uncommon, risks that demand heightened caution and, for some patients, disqualify the drug.

Reading the grade without over-reading it

The practical distance between these two categories shows up in monitoring. Dupilumab and tralokinumab generally require no routine laboratory surveillance, while the oral JAK inhibitors call for baseline and periodic bloodwork and close attention to age, cardiovascular history, malignancy risk, and prior therapy. None of that appears in the two-word phrase "strong recommendation," which is why the phrase is a starting point rather than a verdict. A guideline grade is a synthesis of group-level evidence meant to orient a clinician and an informed patient; it cannot weigh one person's comorbidities, values, and treatment history, which is the work that turns a recommendation into a decision.

Read this way, the 2024 guideline is internally consistent. It can place a biologic and a JAK inhibitor in the same recommendation tier because both clear the bar of confident net benefit for the eligible population, while still expecting that the boxed warning, the monitoring burden, and each patient's risk factors will shape which agent, if any, is chosen. The grading is a map of the evidence, not a ranking of safety.

This article is educational and is not medical advice; decisions about atopic dermatitis therapy belong with a qualified clinician who knows the individual patient.